| 0.575 0.035 (6.48%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.99 | 1-year : | 1.27 |
| Resists | First : | 0.84 | Second : | 1.09 |
| Pivot price | 0.55  |
|||
| Supports | First : | 0.45 | Second : | 0.38 |
| MAs | MA(5) : | 0.55 |
MA(20) : | 0.66 |
| MA(100) : | 1.04 |
MA(250) : | 1.12 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 21.2 |
D(3) : | 17.3 |
| RSI | RSI(14): 30.5 |
|||
| 52-week | High : | 1.75 | Low : | 0.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FIXX ] has closed below upper band by 7.8%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.6 |
| Low: | 0.52 - 0.53 | 0.53 - 0.53 |
| Close: | 0.57 - 0.57 | 0.57 - 0.58 |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Fri, 17 Nov 2023
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Thu, 16 Nov 2023
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to ... - Business Wire
Thu, 16 Nov 2023
Big Pharma-backed startup to go public by merging with gutted Homology - Boston Business Journal - The Business Journals
Thu, 16 Nov 2023
Why Is Rare Disease Focused Homology Medicines (FIXX) Stock Trading Lower Today? - Homology Medicines (NA - Benzinga
Thu, 16 Nov 2023
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely - Simply Wall St
Thu, 16 Nov 2023
Q32 Bio and Homology Medicines Announce Merger Agreement - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 3.091e+007 (%) |
| Held by Institutions | 9.1 (%) |
| Shares Short | 307 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1631e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 984.7 % |
| Return on Equity (ttm) | -36.4 % |
| Qtrly Rev. Growth | 1.96e+006 % |
| Gross Profit (p.s.) | -2795 |
| Sales Per Share | -3667.5 |
| EBITDA (p.s.) | -4.757e+009 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 297770 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|